In the late 1960s, NCI received the modern-day equivalent of billions of dollars to establish a viral oncology program. At the time, the study of the role viruses played in cancer (or whether they played any role at all) was unknown. This could have been either a triumph or a huge and embarrassing waste of...
Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.
